Clopidogrel (Plavix)

Jules Comin, David F Kallmes

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Clopidogrel is an inhibitor of platelet aggregation, indicated for the prevention of ischemic stroke and in-stent thrombosis. However, it has a number of drawbacks, including an increased risk of hemorrhage; a clinical effect that is slow in onset and irreversible; a genetically determined variability in its clinical potency; and interactions with other commonly administered drugs.

Original languageEnglish (US)
Pages (from-to)2002-2004
Number of pages3
JournalAmerican Journal of Neuroradiology
Volume32
Issue number11
DOIs
StatePublished - Dec 2011

Fingerprint

clopidogrel
Platelet Aggregation Inhibitors
Stents
Thrombosis
Stroke
Hemorrhage
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Neurology
  • Radiology Nuclear Medicine and imaging

Cite this

Clopidogrel (Plavix). / Comin, Jules; Kallmes, David F.

In: American Journal of Neuroradiology, Vol. 32, No. 11, 12.2011, p. 2002-2004.

Research output: Contribution to journalArticle

Comin, Jules ; Kallmes, David F. / Clopidogrel (Plavix). In: American Journal of Neuroradiology. 2011 ; Vol. 32, No. 11. pp. 2002-2004.
@article{3edaac8c994e44889f682280a44823b5,
title = "Clopidogrel (Plavix)",
abstract = "Clopidogrel is an inhibitor of platelet aggregation, indicated for the prevention of ischemic stroke and in-stent thrombosis. However, it has a number of drawbacks, including an increased risk of hemorrhage; a clinical effect that is slow in onset and irreversible; a genetically determined variability in its clinical potency; and interactions with other commonly administered drugs.",
author = "Jules Comin and Kallmes, {David F}",
year = "2011",
month = "12",
doi = "10.3174/ajnr.A2913",
language = "English (US)",
volume = "32",
pages = "2002--2004",
journal = "American Journal of Neuroradiology",
issn = "0195-6108",
publisher = "American Society of Neuroradiology",
number = "11",

}

TY - JOUR

T1 - Clopidogrel (Plavix)

AU - Comin, Jules

AU - Kallmes, David F

PY - 2011/12

Y1 - 2011/12

N2 - Clopidogrel is an inhibitor of platelet aggregation, indicated for the prevention of ischemic stroke and in-stent thrombosis. However, it has a number of drawbacks, including an increased risk of hemorrhage; a clinical effect that is slow in onset and irreversible; a genetically determined variability in its clinical potency; and interactions with other commonly administered drugs.

AB - Clopidogrel is an inhibitor of platelet aggregation, indicated for the prevention of ischemic stroke and in-stent thrombosis. However, it has a number of drawbacks, including an increased risk of hemorrhage; a clinical effect that is slow in onset and irreversible; a genetically determined variability in its clinical potency; and interactions with other commonly administered drugs.

UR - http://www.scopus.com/inward/record.url?scp=84455188656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84455188656&partnerID=8YFLogxK

U2 - 10.3174/ajnr.A2913

DO - 10.3174/ajnr.A2913

M3 - Article

C2 - 22135129

AN - SCOPUS:84455188656

VL - 32

SP - 2002

EP - 2004

JO - American Journal of Neuroradiology

JF - American Journal of Neuroradiology

SN - 0195-6108

IS - 11

ER -